CD274 and neoplasm: We conducted a retrospective, observational study to evaluate the real-world prevalence of PD-L1 positivity (evaluated by immunohistochemistry [IHC]) and MSI-H status (evaluated by PCR or IHC) and the association of these biomarkers with overall survival (OS) among immunotherapy-naive patients who received SOC therapy in the same ten advanced tumor types included in the KEYNOTE-158 phase II multicohort study of pembrolizumab monotherapy.